Patents by Inventor Peter Lamb

Peter Lamb has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10438350
    Abstract: The present approach relates, in some aspects, to a multi-level and a multi-channel frame work for segmentation using model-based or “shallow” classification (i.e. learning processes such as linear regression, clustering, support vector machines, and so forth) followed by deep learning. This framework starts with a very low resolution version of the multi-channel data and constructs an shallow classifier with simple features to generate a coarser level tissue mask that in turn is used to crop patches from the high-resolution volume. The cropped volume is then processed using the trained convolution network to perform a deep learning based segmentation within the slices.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: October 8, 2019
    Assignee: General Electric Company
    Inventors: Bhushan Dayaram Patil, Peter Lamb, Roshni Rustom Bhagalia, Bipul Das
  • Patent number: 10397019
    Abstract: In embodiments of an autonomous vehicle platform and safety architecture, safety managers of a safety-critical system monitor outputs of linked components of the safety-critical system. The linked components comprise at least three components, each of which is configured to produce output indicative of a same event independent from the other linked components by using different input information than the other linked components. The safety managers also compare the outputs of the linked components to determine whether each output indicates the occurrence of a same event. When the output of one linked component does not indicate the occurrence of an event that is indicated by the outputs of the other linked components, the safety managers identify the one linked component as having failed. Based on this, the outputs of the other linked components are used to carry out operations of the safety-critical system without using the output of the failed component.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 27, 2019
    Assignee: PolySync Technologies, Inc.
    Inventors: Joshua John Hartung, Peter Brink, Jonathan Lamb, David Paul Miller
  • Publication number: 20190136727
    Abstract: An apparatus configured to control fluid distribution between at least one fluid circulation system (2) associated with equipment (3) and at least two replaceable fluid containers (4), the apparatus having: a fluid path (5) configured to couple to at least one fluid port (6) of the fluid circulation system (2), and to at least one fluid port (7) of each of the replaceable fluid containers (4), the fluid path (5) having at least one valve (8) between the fluid circulation system (2) and at least one replaceable fluid container (4); and a control apparatus (9) configured to control the at least one valve (8) to control the flow of fluid between the fluid circulation system (2) and the at least two replaceable fluid containers (4).
    Type: Application
    Filed: May 13, 2016
    Publication date: May 9, 2019
    Inventors: Gordon Lamb, Rana Ali, Peter Brett, Michael Baker, Marc Payne, John Williams
  • Publication number: 20180374209
    Abstract: The present approach relates, in some aspects, to a multi-level and a multi-channel frame work for segmentation using model-based or “shallow” classification (i.e. learning processes such as linear regression, clustering, support vector machines, and so forth) followed by deep learning. This framework starts with a very low resolution version of the multi-channel data and constructs an shallow classifier with simple features to generate a coarser level tissue mask that in turn is used to crop patches from the high-resolution volume. The cropped volume is then processed using the trained convolution network to perform a deep learning based segmentation within the slices.
    Type: Application
    Filed: June 27, 2017
    Publication date: December 27, 2018
    Inventors: Bhushan Dayaram Patil, Peter Lamb, Roshni Rustom Bhagalia, Bipul Das
  • Publication number: 20180037552
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Application
    Filed: June 9, 2017
    Publication date: February 8, 2018
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Publication number: 20180002289
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide.
    Type: Application
    Filed: June 8, 2017
    Publication date: January 4, 2018
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Patent number: 9809549
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: November 7, 2017
    Assignee: Exelixis, Inc.
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Publication number: 20170275251
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclo-propane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Application
    Filed: June 13, 2017
    Publication date: September 28, 2017
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Publication number: 20170224672
    Abstract: This invention relates to the combination of a C-Met inhibitor and a proteasome inhibitor to treat cancer, particularly multiple myeloma.
    Type: Application
    Filed: August 5, 2015
    Publication date: August 10, 2017
    Inventors: Dana T. Aftab, Peter Lamb
  • Publication number: 20150057310
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Application
    Filed: July 25, 2014
    Publication date: February 26, 2015
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Patent number: 8877776
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane -1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-ffuorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: November 4, 2014
    Assignee: Exelixis, Inc.
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Patent number: 8802692
    Abstract: This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: August 12, 2014
    Assignee: Exelixis, Inc.
    Inventors: Geetha Shankar, Frauke Bentzien, Peter Lamb, David Matthews
  • Publication number: 20140100215
    Abstract: The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.
    Type: Application
    Filed: December 7, 2013
    Publication date: April 10, 2014
    Applicant: Exelixis, Inc.
    Inventors: Dana T. Aftab, A. Douglas Laird, Peter Lamb, Jean-Francois A. Martini
  • Patent number: 8642584
    Abstract: The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.
    Type: Grant
    Filed: August 7, 2012
    Date of Patent: February 4, 2014
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, A. Douglas Laird, Peter Lamb, Jean-Francois A. Martini
  • Patent number: 8513266
    Abstract: The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: August 20, 2013
    Assignee: Exelixis, Inc.
    Inventors: Peter Lamb, David Matthews
  • Patent number: 8481001
    Abstract: The present invention provides methods of treating cancer by administering a compound of Formula I, optionally as a pharmaceutically acceptable salt, solvate and/or hydrate thereof, in combination with other cancer treatments.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: July 9, 2013
    Assignee: Exelixis, Inc.
    Inventors: Peter Lamb, David Matthews
  • Publication number: 20120302545
    Abstract: The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.
    Type: Application
    Filed: August 7, 2012
    Publication date: November 29, 2012
    Applicant: Exelixis, Inc.
    Inventors: Dana T. Aftab, A. Douglas Laird, Peter Lamb, Jean-Francois A. Martini
  • Publication number: 20120035212
    Abstract: Disclosed are malate salts of N-(4-{[6,7-bis(methyloxy)-quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, including a (L)-malate salt, a (D)-malate salt, a (DL) malate salt, and mixtures thereof; and crystalline and amorphous forms of the malate salts. Also disclosed are pharmaceutical compositions comprising at least one malate salts of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide; and methods of treating cancer comprising administering at least one malate salt of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N?-(4-ffluorophenyl)cyclopropane-1,1-dicarboxamide.
    Type: Application
    Filed: January 15, 2010
    Publication date: February 9, 2012
    Applicant: Exelixis, Inc.
    Inventors: Adrian St. Clair Brown, Peter Lamb, William P. Gallagher
  • Publication number: 20110301188
    Abstract: This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, N.J.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, N.J.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR®) and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1-phosphate 1 (S1P1R) receptor antagonists, and at least one antimicrotubule agent.
    Type: Application
    Filed: October 16, 2009
    Publication date: December 8, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Geetha Shankar, Frauke Bentzien, Peter Lamb, David Matthews
  • Patent number: 7999006
    Abstract: The present invention provides methods of treating cancer by administering a compound of Formula I, or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: August 16, 2011
    Assignee: Exelixis, Inc.
    Inventor: Peter Lamb